Monthly reportBOMRA
Botswana Medicines Regulatory Authority — March 2023
What this register recorded from BOMRA in March 2023, what other African authorities published in the same month that bears on it, and what we could not read in BOMRA’s own notices. Every figure here is a count of published regulatory actions. None of it is a finding about Botswana Medicines Regulatory Authority.
What BOMRA published
| Reference | Date | Country | Product | Batches | Action | Class | Source |
|---|---|---|---|---|---|---|---|
| DEA-BW-2023-10424004 | 13 Mar 2023 | BW | Suspected Adverse Drug Reactions of Angiotensin 11 converting enzyme inhibitors reported to BoMRA | none published | Safety communication | Unclassified | Tier 1 · Regulator-published |
| DEA-BW-2023-20632138 | 13 Mar 2023 | BW | Bedaquiline-containing regimenscardiac adverse events | none published | Safety communication | Unclassified | Tier 1 · Regulator-published |
What other authorities published
What we could not read in BOMRA’s notices
- 14 record(s) held from BOMRA in total
- 0 carry no publication date we could read
- 10 name neither a batch nor a stated reason
- 13 name no manufacturer
- 10 are searchable and API-available but carry noindex, because they are too incomplete for a public URL
- 0 have no archived copy of the original notice
Correcting this
Anything on this page that is wrong about Botswana Medicines Regulatory Authority can be corrected by Botswana Medicines Regulatory Authority, and a record published by one of its officers carries verification tier 0 — the rank only the issuing regulator can create. Nothing else on this register does.